Key Takeaways
- • Cinven has agreed to acquire women's healthcare specialist Theramex from Carlyle and PAI Partners in a transaction valued at approximately €2.6bn, according to a Financial Times report.
- • The price is almost double the €1.4bn the sellers paid in 2022, marking a significant realisation for Carlyle and PAI amid a challenging European buyout market.
- • Theramex operates in women's healthcare across menopause, fertility, contraception and osteoporosis, with operations in more than 80 countries across Europe, Asia, Africa and Latin America.
- • Cinven reportedly plans to support further international expansion and product development, targeting underserved areas of women's health.
Summary
Cinven has agreed to acquire Theramex, a London-based women's healthcare specialist, from Carlyle and PAI Partners in a deal valued at approximately €2.6bn, according to a report by the Financial Times. The figure is almost double the €1.4bn the sellers paid when they acquired the company in 2022, a multiple that underscores the value creation achieved during their four-year ownership.
During Carlyle and PAI's ownership, Theramex expanded its product portfolio, streamlined its supply chain and supported growth through acquisitions and new product launches. The exit comes at a time when European sponsors face mounting pressure to return capital to their investors, making the transaction a notable realisation in a challenging buyout environment.
Theramex specialises in women's healthcare treatments spanning menopause, fertility, contraception and osteoporosis. The company operates in more than 80 countries across Europe, Asia, Africa and Latin America, and its portfolio includes hormone replacement therapies and treatments addressing areas of significant unmet medical demand. Cinven reportedly intends to support further international expansion and product development, with a focus on growth in underserved areas of women's health.
The transaction follows a series of major European healthcare buyouts, including CapVest's €10bn acquisition of Stada from Bain Capital and Cinven, and GTCR's €4.1bn purchase of Zentiva from Advent International, indicating continued sponsor appetite for healthcare assets on the continent.
During Carlyle and PAI's ownership, Theramex expanded its product portfolio, streamlined its supply chain and supported growth through acquisitions and new product launches. The exit comes at a time when European sponsors face mounting pressure to return capital to their investors, making the transaction a notable realisation in a challenging buyout environment.
Theramex specialises in women's healthcare treatments spanning menopause, fertility, contraception and osteoporosis. The company operates in more than 80 countries across Europe, Asia, Africa and Latin America, and its portfolio includes hormone replacement therapies and treatments addressing areas of significant unmet medical demand. Cinven reportedly intends to support further international expansion and product development, with a focus on growth in underserved areas of women's health.
The transaction follows a series of major European healthcare buyouts, including CapVest's €10bn acquisition of Stada from Bain Capital and Cinven, and GTCR's €4.1bn purchase of Zentiva from Advent International, indicating continued sponsor appetite for healthcare assets on the continent.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.